Company Profiles

driven by the PitchBook Platform

Avitide

Avitide
2012 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Series E LATEST DEAL TYPE
$12M LATEST DEAL AMOUNT
$28.5M TOTAL AMOUNT RAISED
Description

Developer of a molecule-specific bio-pharmaceutical affinity purification technology designed to improve drug safety and establish biosimilarity. The company bio-pharmaceutical affinity purification technology focuses on purifying therapeutic proteins, enabling rapid development of chromatography resins via chemical synthesis, enabling their partners to achieve faster bioprocess development timelines, reduced program risk, predictable commercial scalability and lower cost of manufacturing for batch and continuous operations.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
16 Cavendish Court
Lebanon, NH 03766
United States

+1 (603) 965-2100
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Avitide’s full profile, request a free trial.

Avitide Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series E) 26-Jun-2017 $12M $28.5M 0000 Completed Generating Revenue
4. Later Stage VC (Series D) 12-Sep-2016 000 000.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 06-Aug-2015 00.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series B) 09-Jun-2014 $3.44M $4.89M $14.7M Completed Startup
1. Early Stage VC (Series A) 04-Mar-2013 $1.45M $1.45M $5.61M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Avitide Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series D 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series B 918,450 $0.000100 $3.74 $3.74 1x $3.74 13.19%
Series A 783,422 $0.000100 $1.87 $1.87 1x $1.87 11.25%
To view this company’s complete Cap Table request access »

Avitide Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Angeli Parvi Angel Group Minority 000 0000 000000 0
Borealis Ventures Venture Capital Minority 000 0000 000000 0
Hoyoung Huh Angel (individual) Minority 000 0000 000000 0
John Ballard Angel (individual) Minority 000 0000 000000 0
Mithril Capital Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Avitide Executive Team (6)

Name Title Board
Seat
Contact
Info
Kevin Isett Ph.D Co-Founder & Chief Executive Officer
Scott Kennedy Chief Financial Officer
Warren Kett Ph.D Co-Founder & Chief Scientific Officer
Jonathan Sheller Co-Founder & Director of Finance and Operations
Dan Freymeyer Head, Business Development
You’re viewing 5 of 6 executives. Get the full list »

Avitide Board Members (7)

Name Representing Role Since Contact
Info
Claudio Nessi Ph.D NeoMed Management Board Member 000 0000
Errik Anderson Self Co-Founder & Board Member 000 0000
Ian Ratcliffe Sands Capital Ventures Board Member 000 0000
Michael Ross Ph.D SV Health Investors Board Member 000 0000
Phil Ferneau JD Borealis Ventures Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »